tradepost.ai Logo
Newsletter InsightsSEC AnalysisAI Top20 IndexPricing
Log in
Start free trial
tradepost.ai Logo

Empowering Traders with AI

Quick Links

Newsletter InsightsSEC AnalysisPricingFAQ

Legal

Privacy PolicyCookies PolicySecurity Disclosure PolicyTerms & ConditionsDisclaimer

Copyright © 2025 Dutchcode B.V. All rights reserved.

10-Q - STRATA Skin Sciences, Inc. (0001051514) (Filer)

Thu, May 15, 10:04 AM (59 days ago)

**STRATA Skin Sciences, Inc. (SSKN) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $6.812 million, up from $6.754 million in Q1 2024. - **Gross Profit:** $3.647 million, up from $3.080 million in Q1 2024. - **Net Loss:** $2.432 million, improved from $3.368 million in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $550,000, an improvement from $804,000 in Q1 2024. **Profit Margins:** - **Gross Margin:** 53.5%, up from 45.6% in Q1 2024. - **Operating Margin:** -29.6%, improved from -42.8% in Q1 2024. **Segment Performance:** - **Dermatology Recurring Procedures:** Revenue up to $4.727 million, gross profit margin at 56.7%. - **Dermatology Procedures Equipment:** Revenue at $2.085 million, gross profit margin at 46.5%. **Cash Flow & Earnings Changes:** - **Operating Cash Flow:** Improved by $254,000. - **Investing Cash Flow:** Improved by $526,000. - **Financing Cash Flow:** No significant changes. **Trends & Uncertainties:** - **COVID-19 Impact:** Ongoing but improving, with most physician offices reopened. - **Russia-Ukraine War & Middle East Conflict:** Supply chain and gas price impacts. - **Trade Policies:** Potential tariffs and trade restrictions affecting costs and demand. **Future Operations:** - **Liquidity:** Management believes current cash and anticipated revenues will meet liquidity needs for the next 12 months. - **Debt:** Senior Term Facility with MidCap, interest-only payments through June 2026, principal payments starting July 2026. - **Equity Distribution Agreement:** Up to $8.9 million of common stock available for sale. **Key Metrics:** - **XTRAC Systems Placed:** 846 in the U.S., down from 864 in Q4 2024. - **TheraClear Devices Placed:** 160 in the U.S., up from 104 in Q1 2024. **Management's Outlook:** - Focus on increasing direct-to-patient advertising for XTRAC. - Continued monitoring of global events and their impact on operations. - Emphasis on cost management and operational efficiency.